The evidence of an association between calcium channel blockers (CCBs) and cancer is conflicting. The objective of the present study was to evaluate the risk of cancer (all, breast, prostate and colon cancers) in association with exposure to CCB.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
This is a population-based cohort study in patients exposed to CCBs from across the UK, using two comparison cohorts: (1) patients with no exposure to CCB (non-CCB) matched on age and gender and (2) unmatched patients unexposed to CCB and at least one other antihypertensive (AHT) prescription. Cancer incidence rates computed in the exposed and the two unexposed groups were compared using HRs and 95% CIs obtained from multivariate Cox regression analyses.
Overall, 150 750, 557 931 and 156 966 patients were included, respectively, in the CCB, non-CCB and AHT cohorts. Crude cancer incidence rates per 1000 person-years were 16. 51, 15. 75 and 10. 62 for the three cohorts, respectively. Adjusted HRs (CI) for all cancers comparing CCB, non-CCB and AHT cohorts were 0. 88 (0. 86 to 0. 89) and 1. 01 (0. 98 to 1. 04), respectively. Compared to the AHT cohort, adjusted HRs (CI) for breast, prostate and colon cancer for the CCB cohort were 0. 95 (0. 87 to 1. 04), 1. 07 (0. 98 to 1. 16) and 0. 89 (0. 81 to 0. 98), respectively. Analyses by duration of exposure to CCB did not show excess risk.
This large population-based study provides strong evidence that CCB use is not associated with an increased risk of cancer. The analyses yielded robust results across all types of cancer and different durations of exposure to CCBs.
BMJ open. 2016 Jan 08*** epublish ***
Lamiae Grimaldi-Bensouda, Olaf Klungel, Xavier Kurz, Mark C H de Groot, Ana S Maciel Afonso, Marie L de Bruin, Robert Reynolds, Michel Rossignol
LA-SER, Paris, France Conservatoire national des arts et métiers (CNAM), Paris, France. , Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. , European Medicines Agency, London, UK. , Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. , Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. , Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands. , Pfizer Epidemiology, New York, New York, USA Tulane University, New Orleans, Louisiana, USA. , Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Canada.